Related Experiment Video
Updated: May 29, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill
Wen Rui Tan1,2, Kei Irie2, Carter McIntire3
1Department of Pharmacology and System Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Insights
Optimizing piperacillin/tazobactam (PTZ) dosing for critically ill pediatric patients during surgery is crucial. New regimens, including lower intermittent doses or continuous infusions, may improve safety and efficacy, addressing concerns about kidney toxicity and dosing practicality.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Pediatric Critical Care
Background:
- Piperacillin/tazobactam (PTZ) is a common perioperative antibiotic prophylaxis in critically ill children.
- Current pediatric intraoperative dosing guidelines for PTZ may pose risks of nephrotoxicity and present practical challenges in clinical settings.
Purpose of the Study:
- To optimize piperacillin/tazobactam (PTZ) dosing regimens in pediatric intraoperative patients using population pharmacokinetic (PK) modeling.
- To evaluate alternative dosing strategies that enhance efficacy and reduce potential adverse events.
Main Methods:
- Population pharmacokinetic (PK) modeling and simulation were employed using piperacillin (PIP) plasma concentration data from 34 pediatric patients.
- A two-compartment model was developed, identifying creatinine clearance as a covariate on clearance and incorporating inter-occasion variability.
Main Results:
- Simulations demonstrated that lower intermittent doses (6-15 mg/kg every 2 hours) or continuous infusions (1.0-2.75 mg/kg/h) achieve target PIP concentrations above 1x MIC for 100% of the dosing interval.
- Higher intermittent doses (25-55 mg/kg every 2 hours) or continuous infusions (3.25-9.25 mg/kg/h) were derived to achieve 100% fT >4× MIC.
Conclusions:
- Model-informed simulations suggest that optimized PTZ dosing, including lower intermittent doses and continuous infusions, are clinically viable.
- These alternative strategies may effectively address current clinical challenges associated with intraoperative PTZ dosing in pediatric patients.
Abstract:
Piperacillin/tazobactam (PTZ) is frequently prescribed during the perioperative period as prophylaxis in critically ill patients. Current international guidelines recommend that the pediatric intraoperative dosing regimen for PTZ be 90-112.5 mg/kg (80-100 mg/kg as piperacillin [PIP]) administered every 2 hours (Q2H). Concerns have been raised not only about the risk of nephrotoxicity due to elevated PIP exposure but also regarding the practicality of adhering to a 2-h dosing interval in clinical settings. To address these concerns, we employed population pharmacokinetic (PK) modeling and simulation approaches to optimize PTZ dosing regimens in pediatric intraoperative patients. PIP plasma concentration data were obtained from 34 patients using an opportunistic sampling strategy. A two-compartment model was found to adequately describe the PK data. Creatinine clearance was identified as a significant covariate on clearance. The inclusion of inter-occasion variability significantly improved model fit. Simulations across body weights of 10-70 kg and creatinine clearance of 20-130 mL/min/1.73 m2 demonstrated that 6-15 mg/kg Q2H, or a 10 mg/kg loading dose followed by 1.0-2.75 mg/kg/h continuous infusion would achieve free PIP concentrations being above the minimum inhibitory concentration (MIC) for 100% of the dosing interval (100% fT >1× MIC). For achieving 100% fT >4× MIC, 25-55 mg/kg Q2H or a 20 mg/kg loading dose followed by 3.25-9.25 mg/kg/h continuous infusion was derived. The model-informed simulations indicated that both lower Q2H doses and continuous infusion methods are clinically viable options and potentially resolve current clinical challenges during intraoperative dosing.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
09:47Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery
Published on: June 2, 2022